Trending...
- Maryland Market Money Program Transitions to the Maryland Department of Agriculture
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
ELKRIDGE, Md. - Marylandian -- NEXS BioMedica Corporation, a leader in pharmaceutical innovation, is calling for urgent reforms to accelerate the development and approval of drugs targeting obesity, a chronic illness affecting over 40% of U.S. adults. The company emphasizes the need for streamlined regulatory pathways to address the growing public health and economic impact of obesity-related diseases.
"Obesity is a complex, chronic condition driving a host of life-threatening illnesses, yet it remains underrecognized and undertreated," said Dr. Marc Nelson, MD, Founder and Chairman of NEXS BioMedica. "Regulatory barriers hinder the timely delivery of innovative therapies to patients who desperately need them."
Repurposing Existing Drugs for Rapid Impact
NEXS BioMedica advocates for repurposing existing drugs with established safety profiles to expedite the creation of effective obesity treatments. Combining proven compounds with advanced delivery technologies, such as slow-release formulations, can reduce development timelines and enhance patient outcomes.
"Repurposing drugs is an underutilized strategy that could deliver solutions faster while ensuring safety and efficacy," Dr. Nelson added.
More on Marylandian
Addressing Regulatory Barriers
The company identifies several challenges that impede progress:
NEXS BioMedica urges agencies like the FDA to expand fast-track programs and prioritize research funding for obesity therapies. By reducing unnecessary delays, these reforms could save lives and reduce the $173 billion annual economic burden of obesity-related healthcare costs.
Collaborating for a Healthier Future
The company also calls for greater collaboration among pharmaceutical firms, healthcare providers, insurers, and policymakers to accelerate innovation and improve patient access to life-changing treatments.
"Addressing obesity as a chronic disease is a medical and economic imperative," said Dr. Nelson. "Streamlining drug development pathways is essential to curbing this epidemic."
About NEXS BioMedica Corporation
NEXS BioMedica is a pharmaceutical and biotechnology company pioneering therapies for weight management, chronic diseases, and metabolic disorders. Under Dr. Marc Nelson's leadership, the company leverages advanced technology to deliver transformative healthcare solutions.
Media Contact:
NEXS BioMedica Corporation
+1-571-580-2911 | media@nexsbiomedica.com | https://www.nexsbiomedica.com
"Obesity is a complex, chronic condition driving a host of life-threatening illnesses, yet it remains underrecognized and undertreated," said Dr. Marc Nelson, MD, Founder and Chairman of NEXS BioMedica. "Regulatory barriers hinder the timely delivery of innovative therapies to patients who desperately need them."
Repurposing Existing Drugs for Rapid Impact
NEXS BioMedica advocates for repurposing existing drugs with established safety profiles to expedite the creation of effective obesity treatments. Combining proven compounds with advanced delivery technologies, such as slow-release formulations, can reduce development timelines and enhance patient outcomes.
"Repurposing drugs is an underutilized strategy that could deliver solutions faster while ensuring safety and efficacy," Dr. Nelson added.
More on Marylandian
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- Maryland State Board of Veterinary Medical Examiners Meeting Notice
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
Addressing Regulatory Barriers
The company identifies several challenges that impede progress:
- Lengthy and expensive clinical trial requirements for chronic conditions.
- Limited expedited pathways for combination therapies or repurposed drugs.
- Insufficient recognition of obesity as a chronic illness requiring long-term treatment.
NEXS BioMedica urges agencies like the FDA to expand fast-track programs and prioritize research funding for obesity therapies. By reducing unnecessary delays, these reforms could save lives and reduce the $173 billion annual economic burden of obesity-related healthcare costs.
Collaborating for a Healthier Future
The company also calls for greater collaboration among pharmaceutical firms, healthcare providers, insurers, and policymakers to accelerate innovation and improve patient access to life-changing treatments.
"Addressing obesity as a chronic disease is a medical and economic imperative," said Dr. Nelson. "Streamlining drug development pathways is essential to curbing this epidemic."
About NEXS BioMedica Corporation
NEXS BioMedica is a pharmaceutical and biotechnology company pioneering therapies for weight management, chronic diseases, and metabolic disorders. Under Dr. Marc Nelson's leadership, the company leverages advanced technology to deliver transformative healthcare solutions.
Media Contact:
NEXS BioMedica Corporation
+1-571-580-2911 | media@nexsbiomedica.com | https://www.nexsbiomedica.com
Source: NEXS BioMedica Corporation
0 Comments
Latest on Marylandian
- Nonprofit innovator named Mensa Executive Director
- Maryland: PUBLIC NOTICE: Unscheduled Mosquito Control Activity in Anne Arundel County
- Yasmine Roulleau named Managing Director in Vancouver, Canada
- Chasing Elizabeth Taylor — The Dazzling True Story Behind the Queen of Diamonds Now Available in Limited-Edition Hardcover
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- TMS Expands Sales Leadership Team with Addition of Meredith Douglas to Drive Growth in Association and Corporate Markets
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Burned-Out to Breakthrough: How Pain 2 Prosperity Authors Illuminate Founder Resilience